Immune Checkpoint Inhibitors Can Be Active in Penile Cancer

WEDNESDAY, Aug. 23, 2023 (HealthDay News) -- Immune checkpoint inhibitors (ICIs) are active in some patients with penile cancer (PeCa), according to a study published online Aug. 11 in the Journal of the National Cancer Institute.
Talal El Zarif, M.D., from the Dana-Farber Cancer Institute in Boston, and colleagues conducted a retrospective study including 92 patients with locally advanced or metastatic PeCa receiving ICIs during 2015 to 2022 across 24 centers in the United States, Europe, and Asia. Overall survival (OS) and progression-free survival (PFS) were estimated, and objective response rates (ORRs) were determined.
Overall, 28, 25, 17, and 16 percent of patients received pembrolizumab monotherapy, combination nivolumab/ipilimumab with or without multitargeted tyrosine kinase inhibitors, nivolumab, or cemiplimab monotherapies, respectively. The researchers found that the median OS was 9.8 months and median PFS was 3.2 months. ORR was 13 and 35 percent in the overall cohort and for those with lymph node-only metastases. Worse OS was seen in association with visceral metastases, Eastern Cooperative Oncology Group performance status ≥1, and higher neutrophil/lymphocyte ratio. Treatment-related adverse events occurred in 29 percent of participants; 9.8 percent were grade 3 or higher.
"The study highlights the importance of high-quality, real-world research to advance therapeutic options for this rare cancer," El Zarif said in a statement. "We are hopeful that response and survival rates will continue to improve for patients fighting penile cancer."
Several authors disclosed ties to the biopharmaceutical and medical technology industries.
Abstract/Full Text (subscription or payment may be required)
Related Posts
AACR: Adding Nivolumab to Neoadjuvant Chemo Slows Resectable NSCLC
TUESDAY, April 12, 2022 (HealthDay News) -- Neoadjuvant nivolumab plus...
A Probiotic May Equal Antibiotics in Fighting Staph Infection
FRIDAY, Jan. 20, 2023 (HealthDay News) -- A probiotic supplement appears to...
Insomnia Partially Explains Link Between Psychotic‑Like Experiences, Suicidal Ideation
WEDNESDAY, Aug. 16, 2023 (HealthDay News) -- Insomnia might be an important risk...
There’s Been a Big Decline in the Rate of Americans Hit by Disability
WEDNESDAY, Feb. 8, 2023 (HealthDay News) -- A new study delivers some great news...